Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial.

Swiss pharma giant Roche has released encouraging results from the Phase III SUNMO study showing Lunsumio (mosunetuzumab) administered subcutaneously in combination with Polivy (polatuzumab vedotin), ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive phase I/II data on NXT007 in people with haemophilia A, supporting its progression into phase III clinical development. NXT007 is a ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Background Despite case series suggesting efficacy, controlled trials of anti-CD20 in lupus and lupus nephritis (LN) have not meet their primary endpoints (Arthritis Rheum 2012;64:1215 and ...

Adding polatuzumab vedotin (Polivy) to standard-of-care treatment significantly improved overall survival (OS) in patients ...

Rituximab has a mechanism of action that is completely different from those of conventional immunosuppressants, and previous retrospective observational studies have suggested the combination of ...

Rituximab is a licensed therapy for granulomatosis with polyangiitis and microscopic polyangiitis but there is limited experience of rituximab in EGPA.Methods EGPA patients from a tertiary centre who ...